Form 4: Leap Therapeutics Executive Granted Stock Options

Christine Granfield, VP, Head of Regulatory Affairs/Quality at Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024.

Summary

• Christine Granfield, VP, Head of Regulatory Affairs/Quality at Leap Therapeutics, was granted an employee stock option on October 2, 2024.
• The option allows her to purchase 85,000 shares of Leap Therapeutics common stock at an exercise price of $2.45 per share.
• The options vest in 36 equal monthly installments, starting one month after the grant date, contingent upon her continued employment with the company.
• The option expires on October 2, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 36 months is typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparing the size of the grant to similar roles at comparable companies (e.g., other small-cap biotech firms) would provide further context on its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates